Pharmacogenomics: an in-house advantage?

Drug Discov Today

Published: January 2006

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1359-6446(05)03699-8DOI Listing

Publication Analysis

Top Keywords

pharmacogenomics in-house
4
in-house advantage?
4
pharmacogenomics
1
advantage?
1

Similar Publications

Background: Pharmacogenomics has demonstrated benefits for clinical care, including a reduction in adverse events and cost savings. However, barriers in expanded implementation of pharmacogenomics testing include prolonged turnaround times and integration of results into the electronic health record with clinical decision support. A clinical workflow was developed and implemented to facilitate in-house result generation and incorporation into the electronic health record at a large academic medical center.

View Article and Find Full Text PDF

Objective: This article describes the implementation of preemptive clinical pharmacogenomics (PGx) testing linked to an automated clinical decision support (CDS) system delivering actionable PGx information to clinicians at the point of care at UCSF Health, a large Academic Medical Center.

Methods: A multidisciplinary team developed the strategic vision for the PGx program. Drug-gene interactions of interest were compiled, and actionable alleles identified.

View Article and Find Full Text PDF

Implementation of pharmacogenomics: Experience at Ochsner Health.

Am J Health Syst Pharm

October 2024

Specialty and Infusion Pharmacies, University of Illinois Health, Chicago, IL, and Department of Pharmacy Practice, University of Illinois Chicago, Chicago, IL, USA.

Purpose: Pharmacogenomics is the study of how individual responses to medication are influenced by genetics. As medication experts, pharmacists are uniquely suited to practicing this application of precision medicine. Fundamental operational aspects of developing a pharmacy clinical pharmacogenomics practice are described, and the specific experience of a multisite health system in developing a pharmacogenomics service is discussed.

View Article and Find Full Text PDF

Cytochrome P450 2D6 (CYP2D6) plays a crucial role in metabolizing approximately 20% of medications prescribed clinically. This enzyme is encoded by the CYP2D6 gene, known for its extensive polymorphism with over 170 catalogued haplotypes or star alleles, which can have a profound impact on drug efficacy and safety. Despite its importance, a gap exists in the global genomic databases, which are predominantly representative of European ancestries, thereby limiting comprehensive knowledge of CYP2D6 variation in ethnically diverse populations.

View Article and Find Full Text PDF
Article Synopsis
  • Cyclosporine A (CsA) is effective for immunity-related diseases but can be toxic to the liver, prompting research into its hepatotoxicity mechanisms.
  • This study used various data from humans, mice, and rats to analyze changes in gene expression and identify pathways affected by CsA over time, focusing on liver microtissues and tissues from different species.
  • Results highlighted specific up-regulated and down-regulated genes and pathways, indicating consistent biological changes across species, which aids in understanding CsA toxicity and advancing biomarker discovery.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!